# Anna Maria Rachiglio

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 38 papers | 1,477 citations | 19 h-index | 38 g-index |
| 50 ext. papers | 1,712 ext. citations | 4.5 avg, IF | 3.77 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 38 | Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.. *Oncologist*, **2022**, 27, 7-12 | 5.7 | 0 |
| 37 | Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma **2020**, 1, 53-70 | | 2 |
| 36 | Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. *Annals of Oncology*, **2020**, 31, 30-40 | 10.3 | 58 |
| 35 | Study of Ras MutationsVPrognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. *Cancers* , **2020**, 12, | 6.6 | 6 |
| 34 | Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. *BMC Cancer*, **2019**, 19, 899 | 4.8 | 8 |
| 33 | Genomic Profiling of Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. *Cancers*, **2019**, 11, | 6.6 | 14 |
| 32 | EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. *Molecular Cancer Therapeutics* , **2019**, 18, 845-855 | 6.1 | 30 |
| 31 | The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. *Cancers*, **2019**, 11, | 6.6 | 27 |
| 30 | Circulating Tumor Cells and ctDNA in NSCLC **2019**, 465-475 | | |
| 29 | The role of circulating free DNA in the management of NSCLC. *Expert Review of Anticancer Therapy*, **2019**, 19, 19-28 | 3.5 | 17 |
| 28 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. *ESMO Open*, **2018**, 3, e000299 | 6 | 24 |
| 27 | RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. *Annals of Oncology*, **2018**, 29, 112-118 | 10.3 | 57 |
| 26 | Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. *BMC Cancer*, **2018**, 18, 828 | 4.8 | 15 |
| 25 | Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. *ESMO Open*, **2017**, 2, e000177 | 6 | 19 |
| 24 | BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. *Cancer Biology and Therapy*, **2016**, 17, 840-8 | 4.6 | 16 |
| 23 | Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. *Annals of Oncology*, **2016**, 27, 1055-1061 | 10.3 | 49 |
| 22 | Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. *Oncotarget*, **2016**, 7, 66595-66605 | 3.3 | 67 |

| | | | |
|---|---|---|---|
| 21 | Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. *ESMO Open*, **2016**, 1, e000086 | 6 | 8 |
| 20 | Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. *BMC Cancer*, **2015**, 15, 26 | 4.8 | 42 |
| 19 | Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. *Annals of Oncology*, **2015**, 26, 1710-4 | 10.3 | 101 |
| 18 | Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. *Pharmacogenomics*, **2015**, 16, 1135-48 | 2.6 | 26 |
| 17 | Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. *Annals of Oncology*, **2014**, 25, 1756-1761 | 10.3 | 91 |
| 16 | Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel **2014**, | | 4 |
| 15 | Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. *Journal of Cellular Biochemistry*, **2013**, 114, 514-24 | 4.7 | 46 |
| 14 | Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. *BioMed Research International*, **2013**, 2013, 385087 | 3 | 27 |
| 13 | The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. *Cancer Biology and Therapy*, **2013**, 14, 1143-6 | 4.6 | 47 |
| 12 | Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. *Journal of Thoracic Oncology*, **2013**, 8, e59-60 | 8.9 | 14 |
| 11 | Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. *PLoS ONE*, **2013**, 8, e80478 | 3.7 | 88 |
| 10 | Comment on Va comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimensV *British Journal of Cancer*, **2012**, 107, 1791-2; author reply 1793-4 | 8.7 | 1 |
| 9 | Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. *International Journal of Oncology*, **2012**, 40, 378-84 | 4.4 | 12 |
| 8 | Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. *Pharmacogenomics and Personalized Medicine*, **2011**, 4, 1-9 | 2.1 | 2 |
| 7 | Letter to the Editor: Reply to Kobunai et al.. *Pharmacogenomics*, **2011**, 12, 309-310 | 2.6 | 1 |
| 6 | Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. *Pharmacogenomics*, **2010**, 11, 1169-79 | 2.6 | 39 |
| 5 | Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. *Breast Cancer Research and Treatment*, **2010**, 123, 387-96 | 4.4 | 34 |
| 4 | Triple negative breast cancer: from molecular portrait to therapeutic intervention. *Critical Reviews in Eukaryotic Gene Expression*, **2010**, 20, 17-34 | 1.3 | 19 |

| | | | |
|---|---|---|---|
| 3 | Leptin signaling in breast cancer: an overview. *Journal of Cellular Biochemistry*, **2008**, 105, 956-64 | 4.7 | 172 |
| 2 | The role of the EGFR signaling in tumor microenvironment. *Journal of Cellular Physiology*, **2008**, 214, 559-67 | 7 | 280 |
| 1 | AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. *Breast Cancer Research and Treatment*, **2007**, 102, 275-82 | 4.4 | 12 |